
Kairos Pharma, Ltd.
KAPAHealthcare|Biotechnology|US
$0.49
+0.03 (+7.33%)
DCF Value
$1.64
Tangible Book / Share
$1.37
Cash / Share
$0.86
Next Earnings Report
Nov 13, 2026
EPS est. -$0.63
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Apr 1, 2026 (424B3). Possible dilution.
Upcoming Data Readouts (1)
Jan 2028
Est. completion
P2Castration-resistant Prostate Cancer
Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
NCT05534646n=116
Recent Press Releases
Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
Nov 5, 2026 · Business Wire
Kairos Pharma Presents at United Scientific Group's 11th International Conference on Cancer Research & Drug Development
Nov 3, 2026 · Business Wire
CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma
Oct 22, 2026 · Newsfile Corp
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Oct 6, 2026 · Business Wire
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
Sep 23, 2026 · Business Wire
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 9, 2026 · Business Wire
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Aug 21, 2026 · Business Wire
SEC Filings (63)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 5, 2026 | 8-K | Material event | DocumentIndex |
| Nov 3, 2026 | 8-K | Material event | DocumentIndex |
| Oct 6, 2026 | 8-K | Material event | DocumentIndex |
| Sep 14, 2026 | 8-K | Material event | DocumentIndex |
| Aug 21, 2026 | 8-K | Material event | DocumentIndex |
| Aug 12, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jul 22, 2026 | 8-K | Material event | DocumentIndex |
| Jul 15, 2026 | 8-K | Material event | DocumentIndex |
| Jun 30, 2026 | 8-K | Material event | DocumentIndex |
| Jun 4, 2026 | 8-K | Material event | DocumentIndex |
| May 26, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| May 22, 2026 | ARS | Annual report to holders | DocumentIndex |
| May 22, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| May 18, 2026 | 8-K | Material event | DocumentIndex |
| May 13, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 11, 2026 | PRE 14A | Proxy / shareholder vote | DocumentIndex |
| Apr 1, 2026 | 424B3 | Offering prospectus | DocumentIndex |
| Apr 1, 2026 | 424B3 | Offering prospectus | DocumentIndex |
| Mar 31, 2026 | 10-K | Annual report | DocumentIndex |
| Mar 2, 2026 | 8-K | Material event | DocumentIndex |
| Feb 26, 2026 | 8-K | Material event | DocumentIndex |
| Jan 23, 2026 | EFFECT | DocumentIndex | |
| Jan 13, 2026 | S-3 | Shelf registration | DocumentIndex |
| Nov 14, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Oct 15, 2025 | 8-K | Material event | DocumentIndex |
| Oct 7, 2025 | 8-K | Material event | DocumentIndex |
| Sep 18, 2025 | 8-K | Material event | DocumentIndex |
| Sep 11, 2025 | 8-K | Material event | DocumentIndex |
| Sep 3, 2025 | 8-K | Material event | DocumentIndex |
| Aug 19, 2025 | 424B3 | Offering prospectus | DocumentIndex |
| Aug 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 12, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Jul 28, 2025 | 10-K/A | Annual report | DocumentIndex |
| Jul 15, 2025 | 8-K | Material event | DocumentIndex |
| Jun 12, 2025 | 8-K | Material event | DocumentIndex |
| Jun 3, 2025 | 8-K | Material event | DocumentIndex |
| May 16, 2025 | DEFR14A | DocumentIndex | |
| May 15, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| May 14, 2025 | 10-Q | Quarterly report | DocumentIndex |
| May 6, 2025 | PRER14A | DocumentIndex |